« Return to News | Awards & Advancement

Intarcia creates vice president and global head of regulatory affairs

Thursday, July 18, 2013 10:02 AM

Biopharmaceutical company Intarcia Therapeutics has hired Dr. Eddie Li to the newly created position of vice president and global head of regulatory affairs. Li brings more than 20 years of experience in regulatory affairs to Intarcia and will be a member of the executive team overseeing the advancement of ITCA 650 (continuous subcutaneous delivery of exenatide) toward successful registration in key markets around the world. ITCA 650 is the company's diabetes drug candidate currently in global phase III clinical trials for the treatment for type 2 diabetes.

Previously, Li was vice president and head of U.S. regulatory affairs at Novo Nordisk, where he was also a member of the leadership team of the U.S. Clinical, Medical, Regulatory and Safety Organization. Li led and managed all regulatory functions across therapeutic areas including diabetes, obesity, hemophilia and inflammation. Li also worked with Sanofi, where he served in a variety of product/therapeutic team leadership and senior strategic advisory roles within global regulatory affairs. He has held the positions of director and head of regulatory development at Johnson & Johnson/McNeil Consumer & Specialty Pharmaceuticals; senior manager, worldwide regulatory affairs at AstraZeneca; and senior toxicologist at Warner-Lambert/Parke-Davis Pharmaceuticals.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.